Aims: To develop and determine safety of gold nanorods whose aspect ratios can be tuned to obtain plasmon peaks between 650 nm and 850 nm, as contrast enhancing agents for diagnostic and therapeutic applications. Materials and methods: In this study we compared the blood clearance and tissue distribution of cetyl trimethyl ammonium bromide (CTAB) capped and poly ethylene glycol (PEG) coated gold nanorods after intravenous injection in the tail vein of rats. The gold content in blood and various organs was measured quantitatively with inductively coupled plasma mass spectrometry (ICP-MS). Results and discussion: The CTAB capped gold nanorods were almost immediately (< 15 minutes) cleared from the blood circulation whereas the PEGylation of gold nanorods resulted in a prolonged blood circulation with a half life time (t 1/2 ) of 19 h and more wide spread tissue distribution. While for the CTAB capped gold nanorods the tissue distribution was limited to liver, spleen and lung, the PEGylated gold nanorods also distributed to kidney, heart, thymus, brain and testes. PEGylation of the gold nanorods resulted in the spleen being the organ with the highest exposure whereas for the non-PEGylated CTAB capped gold nanorods the liver was the organ with the highest exposure, per gram organ.
INTRODUCTION
Nanotechnology is a rapidly developing technology with the potential to provide our society with a wide range of products to be used in various advanced technology applications [1] . More specifically there is a general expectation that significant progress will be made in various medical applications for diagnostic and therapeutic purposes including the potential for specific drug delivery in cancer therapy.
However, besides the beneficial effects of the developed nanodevices also the potential risks should be taken into consideration [2] . For drug delivery nanoformulations may consist of the drug itself or at least two components, one being the pharmaceutical ingredient and the other one being the nanodevice as drug carrier [3] [4] [5] . When nanoparticles are used for diagnostic or therapeutic applications one should realize that after having fulfilled their function the nanomaterials themselves remain and may pose a potential toxicological risk. It is therefore that for drug delivery specifically designed biodegradable nanomaterials are preferable over non degradable solid nanomaterials which may have the potential for local persistence.
Also for diagnostic purposes the nanomaterials should be able to be eliminated from the body either by biodegradation and metabolism or by elimination via excretion [6] .
Kinetic properties are considered to be an important descriptor for potential human toxicity and thus for human health risk. In general, the kinetics of a particle consist of four processes: absorption, distribution, metabolism, and excretion (ADME). It is important to know the amount of the external exposure that is absorbed and results in internal exposure. For therapeutic and diagnostic applications mostly a direct systemic administration into the blood circulation is used, so the whole dose applied should be taken into consideration. Potentially all organs can be reached and are thus considered to be at risk for toxic responses. However, to date most particulate materials in the systemic circulation, including nanoparicles, are taken up by the so called reticulo endothelial system (RES). This results in entrapment of the nanoparticles mainly in organs with a high content of mononuclear phagocytes (macrophages) such as liver and spleen [7] [8] [9] [10] [11] [12] . For diagnostic and therapeutic uses such entrapment in the liver should be avoided unless a specific aim is wanted like treatment of liver diseases. One approach may be to modify the nanoparticles in order to obtain a more specific organ or cellular targeting. The use of carbohydrate binding ligands increased cellular binding of poly(D,L-lactic-co-glycolide)acid (PLGA) nanospheres [13] , whereas the use of specific antibodies enabled a more specific immunologically directed targeting of the nanoparticles [14, 15] . Cellular entrapment in macrophages can be avoided by surface modification of the nanoparticles. Coupling of polyethylene glycol (PEG) onto the surface of nanoparticles was found to increase their circulation time in the blood by inhibiting recognition and phagocytosis by macrophages [16, 17, 18] . Using PEGylation of gold nanorods an increase of gold, as measured by inductively coupled plasma -mass spectrometry (ICP-MS), in both spleen and tumor tissue was observed [17, 19] while the level in the liver was remarkably reduced [17] . In addition, the size of nanoparticles can be a significant determinant of particle distribution, as shown for spherical gold nanoparticles and gold composite nanodevices [7, 20, 21] .
For diagnostic purposes optical imaging is currently under development for detecting, diagnosing, staging, and treatment monitoring of disease. Progression of disease is usually accompanied by changes in physiology and pathology that are manifested as location specific changes in optical properties thereby providing contrast for optical imaging to study disease. Imaging techniques use contrast enhancing agents of which gold nanoparticles have emerged due to their unusual optical properties and inherent biocompatibility [22] [23] [24] .
Gold metal nanoparticles exhibit narrow and intense absorption and scattering bands due to the phenomenon of plasmon resonance, the collective oscillation that the conduction electrons experience in an electromagnetic field of the appropriate wavelength [25] . The plasmon resonant condition of gold nanoparticles depends upon their size, shape, structure (solid or hollow), and upon the refractive index of the embedding medium. Spherical gold nanoparticles have a single plasmon resonant extinction peak at around 520 nm, which does not shift extensively with changes in size and refractive index of the surrounding medium. Due to strong scattering and absorption by hemoglobin, at this wavelength, light penetration in tissue is poor and gold nanospheres are not useful in contrast enhancement for deep tissue imaging.
Rod-shaped nanoparticles exhibit two plasmon resonances due to oscillation of the conduction electrons along the short axis as well as along the long axis of the particles. Thus by tailoring the length and/or width of these particles, their extinction peaks may be made to cover the low-energy visible to infrared wavelength regions [1, 23] . Further, gold-protein chemistry is well developed and several bioconjugation protocols are available in the literature, which allows the combination of the targeting functionality of antibodies with such gold nanoparticles. The inertness and biocompatibility of gold in general hold promise for the use of gold nanoparticles for in vivo imaging applications.
The aim of the present study was to determine the influence of PEGylation of gold nanorods on the blood clearance and tissue distribution and potential organ accumulation in the rat. In this study, we used gold nanorods (AuNR) absorbing in the near infrared region (NIR) of the spectrum (peak absorbing wavelength of ~770 nm).
The PEGylated and non-PEGylated AuNR were intraveneously injected into rats and gold content in various organs was determined by ICP-MS.
MATERIALS, ANIMALS, and METHODS

Materials
We used hexadecyltrimethylammonium bromide (CTAB, product Acros 22716V) for both growth and seed solutions. Gold salt (Tetrachloroauric acid HAuCl 4 .3H 2 O, 99.99%) was purchased from Acros Organics (Belgium), sodium borohydride (NaBH 4 , 99%), and ascorbic acid (99%) from Aldrich (The Netherlands), and silver nitrate (AgNO 3 , 99.8%) from Merck (Germany), methoxy PEG thiol (5000 MW) from Fluka (The Netherlands). Prior to use, all glassware was cleaned with hydrofluoric acid (HF), further with aqua regia (HCl/HNO 3 3:1) and rinsed thoroughly with Milli Q water.
Synthesis of gold nanorods (AuNRs)
In the seed-mediated, surfactant and silver assisted method for the synthesis of AuNR, gold nanospheres produced by fast reduction of gold salt are used to seed a growth solution in the presence of a weak reductant, a facet-selective capping surfactant and silver nitrate (AgNO 3 ) [26] . Specifically, the gold nanospheres are produced by reducing gold salt (tetrachloroauric acid) using sodium borohydride in the presence of surfactant CTAB. The growth solution comprises tetrachloroauric acid, AgNO 3 , with ascorbic acid as weak reducing agent and CTAB as the capping agent. Reduction of gold on the gold seed takes place, but because CTAB assisted by silver passivates certain facets of the seed particles, gold deposition occurs preferentially on the exposed tips to yield rod-shaped particles. [26, 27] . The AuNR which are synthesized by this technique are thus stabilized with a bilayer of CTAB which imparts the particle with a net positive charge and helps maintain colloidal stability due to electrostatic repulsion.
We provide here a short description of the steps involved in the protocol, but more details may be found in [1, 26] . Growth phase: The seed solution (12 µl) was added to the growth solutions with gentle stirring. The resultants were maintained undisturbed at 25 o C for 24 hours after which they were centrifuged twice at 10,000 g/20 minutes and the supernatants removed. The precipitates were re-dispersed in phosphate buffered saline (PBS).
PEGylation of AuNRs
In vitro cell studies [28] [29] [30] 
AuNRs characterization .
Electron microscopy of the AuNRs was performed using a Zeiss-1550 high-resolution scanning electron microscope (HR-SEM). Particle sizes were estimated using the NI Vision module (Labview, National Instruments) on the digital SEM images for which approximately 250 particles were considered.
Optical spectra of nanorods were measured with collimated transmission in a Shimadzu PC3101 UV-Vis-NIR spectrophotometer. The nanorods synthesized had two plasmon peaks, a transverse plasmon peak at approximately 517 nm and a longitudinal plasmon peak at 770 nm. The longitudinal plasmon peak was in the near infrared region (NIR) of the spectrum. The concentrations of non-PEGylated and PEGylated gold nanorods were determined by the optical spectra. The extinction coefficient value of the longitudinal plasmon peak was taken into consideration for calculating the number density (particles/ml). The mean length and width of gold nanorods were measured. The mass of a single AuNR was calculated by multiplying the density of gold with the volume of a rod. The number density was multiplied with the mass of gold nanorods to calculate the concentration of Au in µg/ml.
Zeta potential measurements of AuNRs
Zeta potential reflects the charge present on the surface of nanoparticle. The measurements were carried out using a Malvern Zetasizer Nano Z(S). One ml nanorods were filled in the cuvette (DTS 1060) using a syringe avoiding any airbubbles. The CTAB-AuNR showed positive zeta potential due to the presence of the positively charged CTAB bilayer on the surfaces of the gold nanorods. The PEGylation of gold nanorods caused the displacement of CTAB with PEG and hence the surface charge changes to neutral. The zeta potential of the original CTAB capped gold nanorods (CTAB-AuNR) was (+ 42 ± 7.2) mV, while for the PEGylated gold nanorods (PEG-AuNR) the zeta potential was (+0.4 ± 2.1) mV.
The results of the characterization of the gold nanorods are presented in Table 1 . The optical spectra and a HR-SEM image of the gold nanorods are presented in Figure 1 .
Animals
Six-week-old male Wistar rats (HsdCpb:WU) were purchased from Harlan Nederland BV (Horst, The Netherlands) and allowed to acclimatize for 2 weeks before starting the experiment. Animals were bred under specific pathogen-free (SPF) conditions and barrier maintained during the entire experiment in Macrolon cages at a room temperature of (23 ± 1)°C, a relative humidity of (50 ± 5)% and a 12-hours light/dark cycle. Drinking water and conventional feed were provided ad libitum. The experiment was approved by an independent Ethical Committee on Animal Experimentation and conducted in compliance with all applicable provisions of the national laws, i.e. the Experiments on Animal Decree and the Experiments on Animal Act.
Experimental design
Rats were divided in 3 groups: CTAB-AuNR (n=6), PEG-AuNR (n=6), and PBS vehicle control (n=3). Four days prior to the start of the experiment, a single venous blood sample (tail vein; 100 μl) was obtained from the animals in the control group.
On day 0, rats were intravenously injected (tail vein) with either 1 ml nanogold dispersion or vehicle control. The injections were well tolerated and no adverse effects were observed during the entire experiment. Starting at day 0 venous blood samples were obtained from the treatment-groups at 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 8, 24 (day 1), 48 (day 2), 96 (day 4), and 144 (day 6) hours after injection. Blood samples from the animals in the control group were collected at day "minus" 4 (96 hours before the start of the experiment) and at day 8 (192 hours after start of the experiment). At 24 hours (day 1) and 144 hours (day 6) after the injection, rats (n=12, 6 per treatment group) and at 192 hours (day 8) the 3 control rats were anaesthetized with isoflurane (Isoflu®, AST Pharma, Oudewater, The Netherlands) in oxygen and subsequently euthanized by drawing blood from the abdominal aorta.
Next to blood, liver, spleen, kidneys, lungs, heart, thymus, brain and testes were collected. Organs were weighed and homogenized. All samples were stored at -20°C for determination of the gold content. After subjecting the sample material to a digestion process, the gold content was determined by inductively coupled plasma mass spectrometry (ICP-MS).
Sample pre-treatment and inductively coupled plasma-mass spectrometry (ICP-
MS)
Reagents : All chemicals used for ICP-MS were of analytical grade or of high purity. 
RESULTS
Blood clearance
The blood clearance of the intravenously administered gold nanorods is presented in Figures 2 and 3 . The results show an almost immediate clearance of the CTAB-AuNR gold nanorods from the circulation as at 15 minutes after the administration barely detectable levels of gold were measured in the blood (Figure 2 ). For the PEG-AuNR blood gold levels remain detectable until 48 hours after the administration (Figure 2) . 
Tissue distribution.
The gold concentrations were measured in blood, liver, lungs, spleen, brain, heart, thymus, kidneys and testes at day 1 (t=24 hours) and at day 6 (t=144 hours) after intravenous administration. In control rats (n=3) the gold levels were at or below the detection limit (data not shown).
The gold content in tissues per gram organ is presented in Table 2 . The results show that the CTAB-AuNR are mainly found in the liver and spleen, and to a lesser extent in the lung. Similar levels are observed both on day 1 and day 6 after administration.
Expressed per gram organ the highest exposure is observed in the liver, followed by spleen and lung. For the PEG-AuNR in most organs at t=24 hours and t= 144 hours gold could be detected with the highest levels on day 1 in spleen, blood and liver. At day 6 clearly accumulation in all organs was observed with the highest level in the spleen followed by the liver (Table 2 ).
When we consider the total levels of gold in the whole organ for the PEG-AuNR at day 1 the highest levels are in the blood followed by liver and spleen (Table 3) . In most organs investigated gold could be detected indicating the wide spread distribution of the PEG-AuNR in the body with the highest level per whole organ in the liver (Table 3 ). Both at day 1 and day 6 for the CTAB-AuNR the highest levels are present in the liver at similar magnitude. In addition also in the lung gold could be clearly detected. Table 4 and Figure 4 show the total recovery in organs when compared to the administered dose for day 1 and day 6. The total recovery varied from approximately 70 to more than 100%. However, the recovery might be overestimated. Based on the calculations for the blood clearance for the PEG-AuNR a starting dose of 37.8 μg was calculated. The dose administered according to Table 1 
DISCUSSION
We investigated the blood clearance and tissue distribution of two types of gold nanorods, CTAB capped AuNR and PEGylated AuNR, specifically designed as potential probes for light based imaging techniques [1] . The main finding was the remarkable contrast in blood clearance between the two types: CTAB-AuNR were almost directly removed from the blood circulation, whereas for the PEG-AuNR a blood half time value of 19 hours was observed.
It has been demonstrated with several types of nanoparticles [31] including gold nanoparticles [32, 33] , that when incubated with blood, the particles' surfaces become coated with numerous proteins including immunoglobulins which can enhance recognition and uptake by cells of the reticuloendothelial system (RES). We contend that in our in vivo case with CTAB-AuNR, there is the immediate formation of a serum protein 'corona' [34] [35] [36] comprising opsonin ligands, which initiates the mechanisms of recognition and internalization by components of the RES. This causes rapid clearance of the CTAB-AuNR from blood with deposition into organs of the RES.
When CTAB-AuNR are incubated with mPEG-thiol, strong sulphur binding to the gold surface causes replacement of the CTAB bilayer [30, 37] as seen in the nearneutral zeta-potential values (Table. 1 ). The PEG layer also stabilizes the NRs against aggregation with a steric hindrance mechanism as seen in the retention of the characteristic plasmon peaks after PEGylation (Figure 1 ). The hydrophilic and neutral PEG coating on AuNRs prevents or minimizes adsorption of serum proteins [36, [38] [39] [40] , and also prevents the close approach of the underlying AuNR to cell surfaces [38] . The effect of the PEG coating is then a reduced interaction of the nanocomposite with macrophage cell receptors: PEG-AuNRs thus experience prolonged blood persistence.
This result is in general agreement with recent studies using AuNRs [16] [17] [18] , while there are major differences in the studies. Firstly, Niidome et al. [16] , Akiyama et al. [17] , and Von Maltzahn et al. [18] used mice for the experiments. Secondly, while the PEG lengths used in the studies was the same, the density of the PEG layer on the particles is expected to be different. We used polymer in great excess during PEGylation with PEG:AuNR ratios of approximately 1.5x10 6 :1, to ensure a complete coverage of the gold surfaces. Von Maltzahn et al. [18] actually measured a value around 20,000 per particle, while it appears that Niidome and co-workers [16, 17] used low PEG:AuNR ratios. With these differences, the blood circulation half-life is a parameter which is difficult to compare across these studies. In any case, while we measured 70% of the PEGylated particle dose in the blood 24 hours after injection, Niidome et al. [16] found only 8% and Akiyama et al. [17] found between 20% to 40% at the same time point, while von Maltzahn et al. [18] measured 50% of the injected dose after 20 hours with a circulation half-life time of 17 h comparable with 19 h from this work.
Although for diagnostic use the clearance of imaging contrast agents has to be reasonably fast, the very rapid blood clearance as seen for the CTAB-AuNR greatly diminishes its potential applications considering as well that these particles have been
shown to be toxic in in vitro studies [28] [29] [30] . In this respect the PEG-AuNR show promise as they remain in circulation for some time. The half time of 19 hours allows the nanorods to reach all organs in the body thus widening the possible use as imaging agent.
In addition to the dramatic differences in blood clearance kinetics between the two types of particles, the final organ distribution of the particles was also significantly different. CTAB-AuNR were taken up predominantly by the liver, and to a lesser extent by the spleen followed by the lungs. When expressed as dose per gram organ the highest exposure for CTAB-AuNR was observed in the liver, 1.8 times greater than in the spleen on the 6 th day. (Table 2 ). On the other hand, the PEG-coating of the PEG-AuNR served to shift the distribution profile more towards the spleen with at day 6 a dose per gram organ 6.8 times in excess of that in the liver. This effect on tissue distribution and internal organ dose is especially relevant for the potential toxicity of the used nanomaterials.
As discussed earlier, the CTAB-AuNRs attract a protein corona due largely to their positive charge and and are thus opsonized or tagged for uptake by hepatosplenic macrophages in general, but in particular by the Kupffer cells in the liver [34] [35] [36] . The sequestration of the particles into the liver and spleen is rapid, and occurs within minutes. On the other hand PEGylation of nanoparticles causes a reduced uptake by the Kupffer cells and a promotion of uptake in splenic macrophages. The precise mechanism which directs PEG-AuNR towards clearance by the spleen [41] after a long blood residence time is not clear, but this general trend has been observed now for a few decades for a myriad of nanoparticle types [36, [38] [39] [40] .
Besides the liver and spleen other organs with detectable gold levels were kidney, lung, heart, and to a lesser extent thymus, brain and testes. In the brain the content dropped below the detection level at day 6 after administration. However, we have to realise that low levels expressed as mass or as percentage of the injected dose still may be a considerable amount of nanoparticles. When we look at the 0.19% of the injected dose present in the brain at day 1 after injection, this translates to a number of approximately 2x10 8 PEG-AuNR based on the data presented in Table 1 . When local accumulation in organs would occur this low fraction of the injected dose still may be the cause for a delayed toxic response. The elimination of gold nanoparticles from the liver was reported to be rather slow with a reduction in gold liver content of about 9%
at six months after administration [42] . The percentage recovery of the injected dose was for the PEG-AuNR for other organs than liver and spleen below 2% at day 1 which decreased further below 1% at day 6, indicating the possible elimination of the gold nanorods. In liver and spleen there was a considerable increase in gold content when comparing the gold level at day 6 with day 1.
At autopsy as much blood as possible was collected to maximize removal of residual blood from the organs. The amount of gold in residual blood is included in the measured tissue concentrations. This should be especially considered for the PEGAuNR as these remain in circulation for a prolonged time. Hence, tissue levels could have been overestimated. However, an organ with a high-blood content like the spleen shows at day 1 a higher gold concentration than blood, suggesting that residual blood could have had only a minor effect on the amount of gold measured. On the other hand, the concentrations found in the other organs (liver, kidney, lung, heart, thymus, brain, and testes) were below the concentration in blood. Therefore, contribution of residual blood cannot be ruled out for these organs. For the measurements of the CTAB-AuNR and the day 6 measurements blood levels are too low to have an effect on the tissue measurements. The day 6 measurements clearly show the difference in tissue distribution between the PEG-AuNR and CTAB-AuNR with the PEGylated gold nanorods showing a more widespread tissue distribution. The total recovery at day 6 was relatively low for the PEG-AuNR in contrast to the CTAB-AuNR (Table   4) . This difference might be explained by possible sequestration of the PEG-AuNR in tissues and animal carcass not collected and measured with ICP-MS for their gold content. The high recovery for the CTAB-AuNR can be explained by the almost immediate disappearance of the CTAB-AuNR from the blood and sequestration in the liver. As the liver content remained similar between days 1 and 6 this can explain the high recovery levels for CTAB-AuNR.
The distribution of the gold nanorods in blood and tissue was determined by measuring the gold content of tissue samples by ICP-MS, a method commonly used for the determination of the tissue levels of gold nanoparticles [7, 17, 24, 29] and other metal nanoparticles in biological systems [43] . Other methods used for following the fate of gold nanoparticles are neutron activation either before use [19] so the radionucleide Au [18] . Although the method of neutron activation allows the determination of the gold nanoparticles themselves when the activation of the nanogold preparation is done before the administration to the animals, it also requires specific infrastructures that are not easily available. For INAA the same applies as for ICP-MS that the total gold content is determined and not specifically the gold nanoparticles. For ICP-MS measurement sample preparation (digestion) is needed with e.g. the possibility of loss of the sample due to the used procedure. Determination of the tissue distribution of injected materials is also possible with the use of a radioactive label, which, depending on the label, can be used with a more limited processing method that may limit loss of test sample. For more complex composed nanoparticles there is, however, the possibility for losing the label, as was previously demonstrated for technetium labeled carbon particles used for studying lung passage of inhaled ultrafine particles [45] [46] [47] . As the degradation of the gold seems unlikely the determination of the gold content in organs by ICP-MS is a good measure for the tissue distribution of gold nanomaterials such as gold nanoparticles and nanorods.
CONCLUSIONS
We demonstrated that the coating of gold nanorods with PEG had a significant effect on both the blood clearance and tissue distribution of the gold nanorods. PEGylation of gold nanorods resulted in a prolonged blood circulation with a half life time of 19 hours and more wide spread tissue distribution. PEGylation of the gold nanorods resulted in the spleen being the organ with the highest exposure whereas for the nonPEGylated CTAB capped gold nanorods the liver was the organ with the highest exposure. In view of the time frame (up to 48 h) of the observed increase in blood circulation PEGylated gold nanorods can be considered to be promising candidates for diagnostic imaging purposes.
EXECUTIVE SUMMARY
 PEGylation of gold nanorods prolongs blood circulation time when compared to CTAB capped gold nanorods.  The prolonged circulation time allows for the use of PEGylated gold nanorods as diagnostic imaging agents.  PEGylation of the gold nanorods resulted in the spleen to be the organ with the highest exposure in contrast to the liver.  The increase of spleen exposure by PEGylated nanoparticles needs further investigation in view of possible immunotoxic effects 
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